MBCProject_0471_T1A_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.530
- MYC_TARGETS_V2+0.360
- WNT_BETA_CATENIN_SIGNALING+0.360
- MYC_TARGETS_V1+0.340
- NOTCH_SIGNALING+0.300
- ALLOGRAFT_REJECTION+0.290
- UV_RESPONSE_DN+0.290
- KRAS_SIGNALING_UP+0.280
- INFLAMMATORY_RESPONSE+0.250
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.320
- PEROXISOME-0.310
- P53_PATHWAY-0.280
- DNA_REPAIR-0.250
- HEME_METABOLISM-0.240
- ESTROGEN_RESPONSE_EARLY-0.210
- TNFA_SIGNALING_VIA_NFKB-0.210
- FATTY_ACID_METABOLISM-0.200
- XENOBIOTIC_METABOLISM-0.180
- ESTROGEN_RESPONSE_LATE-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CN-5366-01A-01R-1436-07 | — | — | 0.748 |
| 2 | TCGA-DK-A3IN-01A-11R-A20F-07 | — | — | 0.732 |
| 3 | TCGA-34-5928-01A-11R-1820-07 | — | cohortSQ1 | 0.729 |
| 4 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.722 |
| 5 | SRR23036891 | — | — | 0.717 |
| 6 | b3f7d666-c19c-4dd3-94b7-b85877c8ea28 | — | — | 0.711 |
| 7 | SRR975566 | — | — | 0.711 |
| 8 | TCGA-FD-A62S-01A-11R-A30C-07 | — | — | 0.706 |
| 9 | MDT-AP-3073 | Med | Medulloblastoma | 0.706 |
| 10 | TCGA-GC-A3YS-01A-11R-A23N-07 | — | — | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.170 | Inavolisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.110 | Inavolisib | — uncovered |